Literature DB >> 14617336

Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors.

H Cano1, M J Candela, M L Lozano, V Vicente.   

Abstract

Recent studies have shown that total hepatitis C virus (HCV) core antigen, both free and antibody bound, is an accurate indirect marker of viral replication that can be used in clinical practice. The aim of the present study was to evaluate the performance of a new total HCV core antigen enzyme-linked immunosorbent assay (ELISA) for detection and quantification of total core antigen in blood donors, testing positive for anti-HCV antibodies and for prospective low-risk population screening. A population comprising 257 samples, from blood donors detected reactive for anti-HCV antibodies [137 recombinant immunoblot assay (RIBA) positive and 120 RIBA indeterminate], were tested by using a new total HCV core antigen ELISA. HCV-RNA was quantified by using quantitative polymerase chain reaction (PCR) assays in all RIBA-positive samples and RIBA-indeterminate samples that were positive for the total core antigen. Specificity of the assay was studied in 1070 healthy blood donors negative for anti-HCV antibodies. Compared with quantitative PCR assays, the total HCV core antigen assay showed 97.37% sensitivity. The three HCV-RNA-positive samples, which tested negative for the total core antigen, had a low viral load (< 1.4 x 10(4) IU mL(-1)). All samples with more than 1.4 x 10(4) IU mL(-1) of viral RNA were positive for total core antigen, independent of the HCV genotype. Concentration of total core antigen correlated significantly with those of HCV-RNA (r = 0.614, P < 0.0001). Overall specificity in freshly collected blood donor specimens was 99.63%. Our data indicate that the total HCV core antigen ELISA has a sensitivity close to PCR assays in diagnosing HCV infection in blood donors with anti-HCV antibodies and shows an excellent specificity in volunteer donors. This assay, in combination with anti-HCV antibodies screening tests, could be an alternative to molecular assays for HCV infection screening in blood donors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617336     DOI: 10.1046/j.1365-3148.2003.00452.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  10 in total

1.  Comparison of monolisa HCV Ag/Ab ULTRA with two anti-HCV assays for the detection of HCV infection in hospital setting.

Authors:  Server Yagci; Elizaveta Padalko
Journal:  Curr Microbiol       Date:  2011-11-11       Impact factor: 2.188

2.  Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup.

Authors:  Catherine Gaudy; Catherine Thevenas; Jean Tichet; Nicole Mariotte; Alain Goudeau; Frédéric Dubois
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection.

Authors:  Syria Laperche; Nadine Le Marrec; Annie Girault; Françoise Bouchardeau; Annabelle Servant-Delmas; Michèle Maniez-Montreuil; Pierre Gallian; Thierry Levayer; Pascal Morel; Nicole Simon
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Detection of asymptomatic antigenemia in pigs infected by porcine reproductive and respiratory syndrome virus (PRRSV) by a novel capture immunoassay with monoclonal antibodies against the nucleocapsid protein of PRRSV.

Authors:  Jian-Piao Cai; Ya-Di Wang; Herman Tse; Hua Xiang; Kwok-Yung Yuen; Xiao-Yan Che
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

5.  Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).

Authors:  Mavanur R Suresh; Pravin K Bhatnagar; Dipankar Das
Journal:  J Pharm Pharm Sci       Date:  2008-04-19       Impact factor: 2.327

6.  Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome.

Authors:  Xiao-Yan Che; Li-Wen Qiu; Yu-Xian Pan; Kun Wen; Wei Hao; Li-Ya Zhang; Ya-Di Wang; Zhi-Yong Liao; Xu Hua; Vincent C C Cheng; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

7.  Evaluation of new cases of HCV infection in thalassaemia patients for source of infection.

Authors:  Azita Azarkeivan; Mohsen Nasiritoosi; Sedigheh Amini Kafiabad; Mahtab Maghsudlu; Bashir Hajibeigi; Mohammad Hadizadeh
Journal:  Asian J Transfus Sci       Date:  2011-07

Review 8.  Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies.

Authors:  Shrikant Dashrath Warkad; Keum-Soo Song; Dilipkumar Pal; Satish Balasaheb Nimse
Journal:  Sensors (Basel)       Date:  2019-09-30       Impact factor: 3.576

9.  A rapid point of care immunoswab assay for SARS-CoV detection.

Authors:  Sriram Kammila; Dipankar Das; Pravin K Bhatnagar; Hoon H Sunwoo; Gustavo Zayas-Zamora; Malcolm King; Mavanur R Suresh
Journal:  J Virol Methods       Date:  2008-07-11       Impact factor: 2.014

Review 10.  Recombinant viral proteins for use in diagnostic ELISAs to detect virus infection.

Authors:  Kelly-Anne Spencer; Fernando A Osorio; Julian A Hiscox
Journal:  Vaccine       Date:  2007-03-06       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.